Dashboard
Manage Tickers

CDTX Cidara Therapeutics, Inc.

Nasdaq cidara.com


$ 95.40 $ -2.46 (-2.52 %)    

Friday, 24-Oct-2025 10:44:09 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 617.33 $ 1.33 (0.22 %)
DIA $ 471.46 $ 1.56 (0.33 %)
SPY $ 677.46 $ 0.99 (0.15 %)
TLT $ 91.45 $ -0.11 (-0.12 %)
GLD $ 379.47 $ 1.06 (0.28 %)
$ 96.16
$ 97.00
$ 95.29 x 5
$ 95.92 x 24
$ 93.83 - $ 97.00
$ 11.12 - $ 121.21
858,867
na
2.44B
$ 1.76
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-07-2025 06-30-2025 10-Q
2 05-08-2025 03-31-2025 10-Q
3 03-06-2025 01-01-1970 10-K
4 11-07-2024 09-30-2024 10-Q
5 08-13-2024 06-30-2024 10-Q
6 05-15-2024 03-31-2024 10-Q
7 04-22-2024 12-31-2023 10-K
8 11-02-2023 09-30-2023 10-Q
9 08-03-2023 06-30-2023 10-Q
10 05-11-2023 03-31-2023 10-Q
11 03-23-2023 12-31-2022 10-K
12 11-03-2022 09-30-2022 10-Q
13 08-09-2022 06-30-2022 10-Q
14 05-11-2022 03-31-2022 10-Q
15 03-07-2022 12-31-2021 10-K
16 11-10-2021 09-30-2021 10-Q
17 08-12-2021 06-30-2021 10-Q
18 05-13-2021 03-31-2021 10-Q
19 02-25-2021 12-31-2020 10-K
20 11-05-2020 09-30-2020 10-Q
21 08-13-2020 06-30-2020 10-Q
22 05-13-2020 03-31-2020 10-Q
23 03-04-2020 12-31-2019 10-K
24 11-08-2019 09-30-2019 10-Q
25 08-08-2019 06-30-2019 10-Q
26 05-09-2019 03-31-2019 10-Q
27 02-28-2019 12-31-2018 10-K
28 11-08-2018 09-30-2018 10-Q
29 08-09-2018 06-30-2018 10-Q
30 05-10-2018 03-31-2018 10-Q
31 02-27-2018 12-31-2017 10-K
32 11-08-2017 09-30-2017 10-Q
33 08-09-2017 06-30-2017 10-Q
34 05-10-2017 03-31-2017 10-Q
35 03-15-2017 12-31-2016 10-K
36 11-10-2016 09-30-2016 10-Q
37 08-11-2016 06-30-2016 10-Q
38 05-12-2016 03-31-2016 10-Q
39 03-18-2016 12-31-2015 10-K
40 11-16-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

cidara-therapeutics-presents-data-on--cd388-candidate-at-european-scientific-working-group-on-influenza-in-spain
Cidara Therapeutics Presents Data On CD38...
10/23/2025 12:03:47

Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc ...

hc-wainwright--co-reiterates-buy-on-cidara-therapeutics-maintains-150-price-target
HC Wainwright & Co. Reiterates Buy on Cida...
10/21/2025 16:28:56

HC Wainwright & Co. analyst Sara Nik reiterates Cidara Therapeutics (NASDAQ:CDTX) with a Buy and maintains $150 price ta...

cidara-therapeutics-releases-new-phase-2b-clinical-data-from-its-navigate-study-showing-its-influenza-preventative-candidate-cd388-demonstrated-up-to-761-efficacy-against-influenza-a-and-b-in-healthy-unvaccinated-adults
Cidara Therapeutics Releases New Phase 2b ...
10/21/2025 12:10:33

Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company applying its proprietary Cloudbreak® platform to develop drug-...

morgan-stanley-initiates-coverage-on-cidara-therapeutics-with-overweight-rating-announces-price-target-of-190
Morgan Stanley Initiates Coverage On Cidar...
10/16/2025 13:07:28

Morgan Stanley analyst Maxwell Skor initiates coverage on Cidara Therapeutics (NASDAQ:CDTX) with a Overweight rating and ann...

cidara-therapeutics-analyst-says-lead-influenza-candidate-is-strategically-attractive
Cidara Therapeutics Analyst Says Lead Infl...
10/10/2025 18:11:11

JP Morgan initiated coverage on Cidara Therapeutics with Overweight rating & tgt of $200, citing lead flu asset CD388's...

cidara-therapeutics-surges-ahead-of-eswi-2025-presentation-and-jp-morgan-coverage
Cidara Therapeutics Surges Ahead of ESWI 2...
10/10/2025 14:55:59

Cidara Therapeutics Inc (NASDAQ:CDTX) shares are trading higher on Friday after the biotech company made a recent announcement ...

cidara-therapeutics-to-present-cd388-navigate-phase-2b-influenza-data-at-eswi-2025-showcasing-cloudbreak-dfc-platform-in-late-breaking-abstract
Cidara Therapeutics To Present CD388 NAVIG...
10/10/2025 12:14:57

jp-morgan-initiates-coverage-on-cidara-therapeutics-with-overweight-rating-announces-price-target-of-200
JP Morgan Initiates Coverage On Cidara The...
10/10/2025 11:32:13

JP Morgan analyst Anupam Rama initiates coverage on Cidara Therapeutics (NASDAQ:CDTX) with a Overweight rating and announces...

wbb-securities-maintains-strong-buy-on-cidara-therapeutics-raises-price-target-to-199
WBB Securities Maintains Strong Buy on Cid...
10/09/2025 18:33:40

WBB Securities analyst Steve Brozak maintains Cidara Therapeutics (NASDAQ:CDTX) with a Strong Buy and raises the price targe...

hc-wainwright--co-maintains-buy-on-cidara-therapeutics-raises-price-target-to-150
HC Wainwright & Co. Maintains Buy on Cidar...
10/09/2025 14:50:58

HC Wainwright & Co. analyst Sara Nik maintains Cidara Therapeutics (NASDAQ:CDTX) with a Buy and raises the price target ...

fda-grants-breakthrough-therapy-designation-for-cidaras-cd388-for-preventing-influenza-a--b-in-high-risk-populations
FDA Grants Breakthrough Therapy Designatio...
10/09/2025 12:02:37

Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc ...

cidara-shares-are-trading-higher-friday-whats-going-on
Cidara Shares Are Trading Higher Friday: W...
10/03/2025 16:53:54

Cidara shares are trading higher Friday after the company secured $339 million in BARDA funding to advance its CD388 pandemic i...

jmp-securities-maintains-market-outperform-on-cidara-therapeutics-raises-price-target-to-173
JMP Securities Maintains Market Outperform...
10/03/2025 12:07:49

JMP Securities analyst Roy Buchanan maintains Cidara Therapeutics (NASDAQ:CDTX) with a Market Outperform and raises the pric...

cidara-secures-up-to-339m-barda-award-to-advance-cd388-pandemic-influenza-therapeutic-and-us-manufacturing
Cidara Secures Up To $339M BARDA Award To ...
10/02/2025 20:06:30

Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc ...

hc-wainwright--co-maintains-buy-on-cidara-therapeutics-raises-price-target-to-110
HC Wainwright & Co. Maintains Buy on Cidar...
09/26/2025 10:44:24

HC Wainwright & Co. analyst Sara Nik maintains Cidara Therapeutics (NASDAQ: CDTX) with a Buy and raises the price target...

cidara-therapeutics-announces-first-participants-dosed-in-phase-3-trial-to-evaluate-safety-and-efficacy-of-cd388-non-vaccine-preventative-of-seasonal-influenza-in-high-risk-populations
Cidara Therapeutics Announces First Partic...
09/25/2025 20:03:26

- Phase 3 study expected to enroll 6,000 participants starting in the Northern Hemisphere- Participants will include adults ove...

guggenheim-maintains-buy-on-cidara-therapeutics-raises-price-target-to-167
Guggenheim Maintains Buy on Cidara Therape...
09/25/2025 12:56:16

Guggenheim analyst Seamus Fernandez maintains Cidara Therapeutics (NASDAQ: CDTX) with a Buy and raises the price target from...

needham-maintains-buy-on-cidara-therapeutics-raises-price-target-to-100
Needham Maintains Buy on Cidara Therapeuti...
09/24/2025 16:10:22

Needham analyst Joseph Stringer maintains Cidara Therapeutics (NASDAQ:CDTX) with a Buy and raises the price target from $74 ...

wbb-securities-reiterates-strong-buy-on-cidara-therapeutics-maintains-123-price-target
WBB Securities Reiterates Strong Buy on Ci...
09/24/2025 11:22:28

WBB Securities analyst Steve Brozak reiterates Cidara Therapeutics (NASDAQ:CDTX) with a Strong Buy and maintains $123 price ...

cidara-therapeutics-announced-updates-to-its-planned-phase-3-registrational-trial-of-cd388-following-its-end-of-phase-2-meeting-with-fda
Cidara Therapeutics Announced Updates To I...
09/24/2025 11:09:04

Cidara is proceeding with an expanded and accelerated development plan seeking biologics license application (BLA) approval bas...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION